EMG
KDNY

Ellington Management Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ellington Management Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,857
Closed -$364K – 860
2016
Q3 		$364K Buy
+5,857
New +$414K 0.1% 386

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ellington Management Group's KDNY Position: Q4 2016 in Review

Ellington Management Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2016, closing a stake of 5,857 shares — an estimated $364K sold.

Ellington Management Group first reported a position in KDNY in Q3 2016 and held it in 1 quarter. The position peaked at $364K in Q3 2016. 87 funds tracked by Wall St. Rank hold KDNY as of Q4 2016.

  • Ellington Management Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Ellington Management Group sold 5,857 Chinook Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $364K.
  • Ellington Management Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Ellington Management Group's Chinook Therapeutics, Inc. Common Stock position peaked at $364K in Q3 2016.
  • 87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Ellington Management Group's 13F filing for Q4 2016, filed 14 Feb 2017.